Skip to content

A CLINICAL TRAIL TO COMPARE LOW DOSE PROPOFOL AND ETOMIDATE ON VARIOUS PARAMETERS OF ELECTROCONVULSIVE THERAPY

COMPARISON OF LOW DOSE PROPOFOL AND ETOMIDATE IN ELECTROCONVULSIVE THERAPY A DOUBLE BLINDED RANDOMISED CONTROLLED CROSSOVER TRIAL - PEEC

Status
Active, not recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/01/039097
Enrollment
44
Registered
2022-01-03
Start date
Unknown
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F314- Bipolar disorder, current episodedepressed, severe, without psychotic features Health Condition 2: F311- Bipolar disorder, current episodemanic without psychotic features Health Condition 3: F23- Brief psychotic disorder Health Condition 4: F331- Major depressive disorder, recurrent, moderate Health Condition 5: F323- Major depressive disorder, singleepisode, severe with psychotic features Health Condition 6: F322- Major depressive disorder, singleepisode, severe withou

Interventions

Intervention1: Low dose propofol in electroconvulsive therapy: Propofol in the dose of 1mg/kg is given for one session of Electroconvulsive therapy, seizure duration is noted Control Intervention1: Et

Sponsors

Dr Praveen Onimath
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: ASA Physical status I and II Age 20-65 years Informed valid written consent taken from patients attenders

Exclusion criteria

Exclusion criteria: History of allergy to given drug History of cardiovascular diseases History of cerebrovascular diseases with raised ICT Uncontrolled seizures on antiepileptics Patients on pacemaker Neuromuscular diseases

Design outcomes

Primary

MeasureTime frame
To assess the effects of low dose propofol and etomidate on seizure duration and seizure thresholdTimepoint: HR, BP, SPO2 are noted after the administration of study drug, after giving succinylcholine, then after ECT, at 1, 3, 5,7, 10 min, and then every 5 min throughout the procedure.

Secondary

MeasureTime frame
To study hemodynamic data recovery characteristics and adverse effects if any.Timepoint: Hemodynamic data during the procedure and recovery characteristics and adverse effects at end of the procedure are seen.

Countries

India

Contacts

Public ContactDr Swarnamba UN

Karnataka Institute Of Medical Sciences Hubli

drswarnmba@rediffmail.com9448559776

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026